Cardiac Magnetic Resonance Imaging in Patients With Non-Hodgkin Lymphoma or Hodgkin Lymphoma Receiving Doxorubicin

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

10 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-01-01

Study Completion Date

2013-02-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RATIONALE: Diagnostic procedures, such as cardiac magnetic resonance imaging, may help doctors detect early changes in the heart caused by chemotherapy.

PURPOSE: This clinical trial is studying how well cardiac magnetic resonance imaging works in patients with newly diagnosed non-Hodgkin lymphoma or Hodgkin lymphoma receiving doxorubicin.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Cardiac Fibrosis by CMR in Patients With Cancer

NCT01906437

Lymphoma

WITHDRAWN

Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy

NCT05414162

DLBCL Multiple Myeloma Cytokine Release Syndrome +6 more

RECRUITING

Diagnostic Utility of Exercise Cardiac Magnetic Resonance in the Assessment of Cardiac Dyspnea.

NCT03951779

Shortness of Breath Cardiac; Dyspnea

COMPLETED NA

Cardiac Magnetic Resonance Monitoring of Immune Checkpoint Inhibitor-related Cardiotoxicity

NCT06132984

Immune Checkpoint Inhibitors, Cardiotoxicity

RECRUITING

Evaluation of Myocardial Injury After Anthracycline Chemotherapy in Osteosarcoma Patients Using CMR

NCT04461223

Cardiotoxicity Osteosarcoma Myocardial Injury +2 more

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

OBJECTIVES:

* To determine whether early myocardial structural and functional changes can be detected using cardiac MRI in patients with newly diagnosed non-Hodgkin lymphoma or Hodgkin lymphoma receiving doxorubicin hydrochloride-based chemotherapy.

OUTLINE: Patients undergo cardiac MRI with gadolinium contrast prior to initiation of doxorubicin hydrochloride-based chemotherapy and 3 months after completion of six courses of chemotherapy for non-Hodgkin lymphoma and twelve courses of chemotherapy for Hodgkin lymphoma.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiac Toxicity Chemotherapeutic Agent Toxicity Lymphoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Observational

Only had observational arm

contrast-enhanced magnetic resonance imaging

Intervention Type PROCEDURE

Cardiac magnetic resonance imaging (cMRI) offers the unique advantage of being able to analyze both function and structure (myocardial changes in the form of both a functional decrease in ejection fraction and structural changes within the myocardium defined as delayed contrast uptake). Participants will have already received doxorubicin hydrochloride as standard therapy when undergoing chemotherapy for non-Hogdkin's lymphoma and Hogdkin's lymphoma.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

contrast-enhanced magnetic resonance imaging

Cardiac magnetic resonance imaging (cMRI) offers the unique advantage of being able to analyze both function and structure (myocardial changes in the form of both a functional decrease in ejection fraction and structural changes within the myocardium defined as delayed contrast uptake). Participants will have already received doxorubicin hydrochloride as standard therapy when undergoing chemotherapy for non-Hogdkin's lymphoma and Hogdkin's lymphoma.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of non-Hodgkin lymphoma or Hodgkin lymphoma

o Newly diagnosed disease
* Planning to receive doxorubicin hydrochloride-based chemotherapy solely at the University of Nebraska Medical Center
* Fertile patients must use effective contraception
* Able to lie flat for 90 minutes
* Able to fulfill the requirements of the study

Exclusion Criteria

* Not pregnant or nursing
* No pacemaker
* No chronic kidney disease stages 3-5 (glomerular filtration rate \< 60 mL/min)
* No metallic foreign body not approved for MRI
* No known hypersensitivity to gadolinium contrast or other required drugs in the study
* No comorbidity or condition which, in the opinion of the investigator, may interfere with the assessments and procedures of this study
* No prior chemotherapy
* No prior radiotherapy to mantle or mediastinum

Minimum Eligible Age

19 Years

Maximum Eligible Age

120 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes